BACKGROUND: Plasma myeloperoxidase (MPO), an inflammatory biomarker, is associated with increased mortality in patients with acute coronary syndrome or chronic left ventricular systolic dysfunction. We sought to assess the diagnostic accuracy of MPO for acute decompensated heart failure (ADHF) and its prognostic value for patients with acute dyspnea.
Inflammatory mediators that coordinate the innate immune response play key roles in the pathophysiology of coronary disease and heart failure. Myeloperoxidase (MPO) 5 is released from activated neutrophils and monocytes during inflammation and has been identified as a novel inflammatory marker (1 ) . MPO increases the oxidative potential of hydrogen peroxide by generating hydrochlorous acid through the peroxidation of chloride, providing a powerful bactericidal antagonist to a wide range of pathogens.
In coronary artery disease, MPO has been implicated in initiating and propagating atherosclerosis. The enzyme promotes LDL oxidation, which leads to the formation of foam cells, fatty streaks, and atheromas (2, 3 ) . MPO may also increase plaque vulnerability and promote thrombosis (4, 5 ) . Consequently, the plasma concentration of MPO has prognostic utility for patients with chest pain or acute coronary syndromes and may serve as an early diagnostic marker in this setting (6, 7 ) . An increased MPO concentration is a predictor of higher mortality after myocardial infarction, independent of left ventricular ejection fraction (LVEF) and serum N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentration (8 ) .
The role of inflammation and MPO in heart failure is less well defined. It is clear that inflammatory mediators generate reactive oxygen species, which may worsen myocardial function by causing protein dysfunction, fibrosis, nitric oxide depletion, and myocyte apoptosis (9 ) . Plasma MPO concentrations are increased in compensated chronic systolic dysfunction, and higher concentrations are predictive of mortality and adverse outcomes, such as the necessity for cardiac transplantation (10, 11 ) . Higher MPO concentrations are also associated with an increased prevalence of severe diastolic dysfunction and right ventricular systolic dysfunction (11 ) . Furthermore, plasma markers of oxidative stress are increased in acute decompensated heart failure (ADHF) (12, 13 ) . The purposes of this study were first to investigate the diagnostic and prognostic value of circulating MPO concentrations in patients presenting with dyspnea to the emergency department (ED) and, second, to evaluate the additive prognostic value of MPO concentration in combination with established natriuretic peptide biomarkers and measures of cardiac function.
Materials and Methods

STUDY DESIGN AND PATIENTS
The study was a prospective cohort study conducted in 5 centers in the US. The research was approved by the institutional review boards of the participating study centers. The study enrolled a convenience sample of 412 patients from May 2003 through December 2006.
Patients were included if they were Ն18 years old and had presented to an ED setting with a primary complaint of dyspnea. We excluded both patients with overt causes of dyspnea, including trauma, pneumothorax, or upper airway obstruction, and patients with acute coronary syndromes. Acute coronary syndrome was defined as a clinical suspicion of cardiac ischemia or infarction accompanied by either (a) an ST-segment deviation of Ն1 mm or (b) a serum troponin concentration increased above the upper limit of the reference interval for the local laboratory. Written informed consent was obtained from all patients enrolled in the study.
A designated study coordinator obtained data from the medical record and by querying patients directly. Pertinent data included demographic information, symptoms, physical examination findings, vital signs, medical history, electrocardiograms, chest x-ray reports, and medication status. Information about the patient's race was entered if the patient reported it. We used these data to adjust multivariate models of prognosis and to calculate the estimated glomerular filtration rate, which was calculated from the Modification of Diet in Renal Disease equation (14 ) . The patient's status at the 12-month follow-up was assessed by telephone interview, a review of medical records, and a search of the Social Security Death Index to identify the time to death, if applicable.
BLOOD SAMPLES AND ASSAYS
At the time of patient enrollment, 20 mL of blood was collected into plastic tubes [EDTA-containing, heparin-coated, and plain (for serum) tubes], centrifuged within 2 h, and stored at Ϫ20°C or colder. The frozen samples were shipped on dry ice to the Core Laboratory at the University of Maryland School of Medicine and maintained at Ϫ70°C until measurement. The samples were thawed once in a room-temperature water bath and assayed within 1 h.
MPO in EDTA-containing plasma collected into plastic tubes was measured by immunoassay on the Dimension RxL system (Siemens Healthcare Diagnostics). We carried out a 20-day in-house precision study according to the CLSI EP5-A2 guideline (http://www. clsi.org/source/orders/free/ep5-a2.pdf) and obtained MPO within-run and total imprecisions of 3.8% and 4.8%, respectively, at 428 pmol/L (n ϭ 80), and 3.3% and 3.6%, respectively, at 3643 pmol/L. The detection limit was 13 pmol/L, and the assay was linear to 5223 pmol/L. The concentration of BNP in EDTAcontaining plasma was measured with Triage BNP 2-site immunoassay reagents (Biosite) formatted for Beckman Coulter instrumentation. The BNP measurements were performed on an Access II system (Beckman Coulter) in strict accordance with the manufacturer's instructions. The concentration of NT-proBNP in plain serum was measured with the 1-step immunometric Dimension PBNP sandwich assay (Dimension RxL system; Siemens Healthcare Diagnostics) in accordance with the manufacturer's instructions. All blood samples were processed by personnel blinded from any patient data.
NT-proBNP and BNP values were divided into classes that were "negative," "gray-zone" (intermediate), or "positive" for predicting cardiac dyspnea. For NT-proBNP, the age-based cutoffs for diagnosing heart failure have been established elsewhere (Ͼ450 ng/L for patients Ͻ50 years, Ͼ 900 ng/L for patients 50 -70 years, and Ͼ1800 ng/L for patients Ͼ70 years). NT-proBNP concentrations Ͻ300 ng/L are considered negative for cardiac dyspnea, and values between 300 ng/L and the age-based cutoff value represent grayzone concentrations (15 ) . For BNP, concentrations Ͻ100 ng/L have been shown to have a strong negative predictive value for ADHF, whereas values Ͼ500 ng/L strongly predict ADHF (16 ) . Values of 100 -500 ng/L were considered intermediate (17 ) .
ECHOCARDIOGRAPHY
Prospective echocardiography evaluations were planned for all patients within 96 h of enrollment. The echocardiograms were performed by an experienced sonographer, and the VHS tapes or digital images were sent to the core laboratory (University of Maryland). To minimize interobserver variability, we had a single investigator blinded from the clinical data interpret all of the images and perform all of the measurements.
Simpson biplane analysis was used to determine the LV end-systolic volume (LVESV) and the LV enddiastolic volume (LVEDV) (18 ) . The LVEF was calculated as:
LV mass was measured according to the M-mode criteria recommended by the American Society of Echocardiography and the formula proposed by Devereux et al. (19 ) . The LV mass was indexed to body surface area.
Diastolic function was assessed in the apical 4-chamber view. Doppler evaluations of mitral inflow velocities and tissue Doppler imaging sampling from the lateral mitral annulus were obtained to grade the severity of diastolic dysfunction as stage I [impaired relaxation, ratio of transmitral peak flow velocity in early diastole to peak flow velocity in late diastole (E/A ratio) Ͻ1, deceleration time (Dt) Ͼ220 ms], stage II] pseudonormal, E/A ratio between 1 and 2, Dt Ͻ220 ms, early diastolic mitral annular velocity (Em) Ͻ8.5 m/s], or stage III (restrictive, E/A ratio Ͼ2, Dt Ͻ150 ms) (20 ) .
DIAGNOSIS OF HEART FAILURE AND STRUCTURAL CARDIAC
DEFECTS
An expert panel of physicians trained in cardiovascular medicine diagnosed ADHF by means of a standardized adjudication form. The physicians were not directly involved in the care of the patients and were blinded to the biomarker results and the diagnosis of the ED physician. Two panel members reviewed the presenting signs and symptoms, the medical history, medications, and echocardiography and electrocardiography results and diagnosed ADHF according to the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial criteria (21 ) . A third expert was used to determine the final diagnosis if the 2 experts disagreed. The panel of physicians also identified patients with structural heart disease from the clinical data and assessments of echocardiographic parameters of LV systolic function (LVEF Յ40%), valvular disease, and the presence of myocardial hypertrophy.
STATISTICAL ANALYSIS
Continuous variables are presented as the mean (SD), and categorical variables are presented as percentages. MPO values were not normally distributed and were therefore logarithmically transformed before parametric analyses. Patients with ADHF, patients with cardiac structural defects without ADHF, and patients with neither ADHF nor cardiac structural defects were compared with 1-way ANOVA and subsequent betweengroup t-tests. Variances were not pooled across groups if heterogeneity of variances was observed (Levene P Ͻ 0.01). Associations of MPO concentration with clinical, biochemical, and echocardiographic variables were evaluated with Spearman nonparametric correlation coefficients. Linear regression analysis was used to adjust for clinical characteristics, including age, race, sex, and body mass index (BMI). To examine diagnostic properties, we used ROC curves to examine whether MPO and other biomarkers were associated with ADHF and structural cardiac abnormalities, and we used the area under the ROC curve (AUC) and the c statistic as indicators of accuracy.
We used Cox proportional hazards models to assess the predictive value of the biomarkers for mortality and adjusted for the same clinical characteristics used in the linear regression analysis. Separate models were examined for MPO, BNP, and NT-proBNP, and the final multivariate model examined the relative contribution of all biomarkers and covariates. Statistical analysis was performed with SPSS software, version 14.0. ] (P Ͻ 0.001). Although the history of prior myocardial infarction or heart failure was more prevalent in patients with ADHF (29% and 42%, respectively) or structural heart disease (29% and 39%) than in those without cardiac abnormalities (19% and 31%), these differences between groups did not reach statistical significance (P ϭ 0.07, and P ϭ 0.11, respectively). The prevalences of heart failure risk factors, diabetes mellitus (30%), and hypertension (65%) did not differ when the groups were compared on the basis of the presence or absence of ADHF (P ϭ 0.53, and P ϭ 0.86, respectively).
Results
PATIENTS
CLINICAL CORRELATES OF MPO
The median MPO concentration was 566 pmol/L [interquartile range (IQR), 414 -827 pmol/L]. MPO was weakly but significantly associated with New York Heart Association class-based dyspnea severity (r ϭ 0.17; P ϭ 0.001). In a subgroup analysis, MPO concentration was weakly associated with dyspnea severity in patients without ADHF or structural heart disease (r ϭ 0.23; P ϭ 0.001), but not in patients with ADHF (r ϭ 0.09; P ϭ 0.28) or structural heart disease (r ϭ 0.11; P ϭ 0.45). MPO concentration was also weakly associated with female sex (r ϭ 0.12; P ϭ 0.02), BMI (r ϭ 0.14; P ϭ 0.005), and heart rate (r ϭ 0.16; P ϭ 0.002) ( Table 2 ). Multivariate analyses indicated that the relationship between the severity of dyspnea and MPO concentration remained significant (r ϭ 0.13; P ϭ 0.014), whereas associations with age, sex, and BMI were no longer significant.
MPO AND DIAGNOSIS OF HEART FAILURE AND STRUCTURAL
HEART DISEASE
MPO concentrations in patients without ADHF (median, 576 pmol/L; IQR, 413-884 pmol/L) were similar to those of ADHF patients (median, 553 pmol/L; IQR, 415-738 pmol/L) (P ϭ 0.07). In contrast, BNP and NT-proBNP concentrations were significantly higher in ADHF patients (P Ͻ 0.001 for both BNP and NTproBNP; Fig. 1 ). For the entire patient cohort, MPO concentration was correlated with neither NT-proBNP concentration (r ϭ Ϫ0.02; P ϭ 0.72) nor BNP concentration (r ϭ Ϫ0.04; P ϭ 0.56). ROC curves for the diagnosis of ADHF indicated that BNP (AUC ϭ 0.90; P Ͻ 0.001) and NT-proBNP (AUC ϭ 0.90; P Ͻ 0.001) had excellent diagnostic value as markers for ADHF, whereas MPO was not useful in this regard (AUC ϭ 0.46; P ϭ 0.18) (Fig. 2) . For patients without ADHF, the MPO values of patients with and without structural heart disease did not differ (P ϭ 0.93). 
Fig. 1. Box-and-whisker plots of MPO (A), BNP (B), and NT-proBNP (C) biomarker concentrations according to diagnosis.
The boxes represent the IQR, the horizontal lines represent the median, and the vertical lines represent the range in values.
Myeloperoxidase and Prognosis
Echocardiography results were obtained for 338 patients (82%). MPO concentration was not correlated with LVEF, LVESV, or LVEDV (Table 3 ). MPO concentration showed a weak inverse association with LV mass index that was statistically significant only in patients with neither structural heart disease nor ADHF (r ϭ Ϫ0.18; P ϭ 0.03). MPO concentrations in patients with diastolic dysfunction (median, 539 pmol/L; IQR, 415-799 pmol/L) were not significantly different from those in patients without diastolic dysfunction (median, 589 pmol/L; IQR, 413-896 pmol/L) (P ϭ 0.22), nor was MPO concentration associated with the stage of diastolic dysfunction (r ϭ Ϫ0.06; P ϭ 0.32).
PROGNOSIS OF MPO FOR 1-YEAR MORTALITY
Complete follow-up data were available for 401 (97%) of 412 patients. Fifty-one patients (12%) with a validated follow-up status died. The c statistic value for MPO prediction of mortality was not significant (AUC, 0.52; P ϭ 0.58) (Fig. 3) . MPO did not appear to be a significant predictor of mortality [hazard ratio, 1.25 (comparing groups above vs below the MPO median); 95% CI, 0.71-2.18]. Stratified analyses for the 3 patient groups revealed no relationships between MPO concentration and mortality (P values Ͼ0.20).
In contrast, BNP [hazard ratio, 2.87 (above vs below the median); 95% CI, 1.55-5.30] and NT-proBNP [hazard ratio, 3.11 (above vs below the median); 95% CI, 1.66 -5.87] were significantly related to mortality. Furthermore, both natriuretic peptide tests remained significant predictors of mortality in Cox proportional hazards analysis after adjustment for age, race, sex, and BMI. The addition of MPO concentration to the prognostic models provided no added predictive value (P Ͼ 0.20; see clinchem.org/content/vol55/issue1), even when natriuretic peptide values were stratified into known diagnostic/prognostic subgroups (negative vs gray zone vs positive).
Discussion
Our results demonstrated that circulating MPO concentrations provided no diagnostic or prognostic information in the evaluation of ED patients presenting with dyspnea. Importantly, MPO concentration contributed no added predictive value to a clinical model that included demographic variables and natriuretic peptide assessment. This finding is of particular interest because accumulated data have shown a potential diagnostic and prognostic role for inflammatory markers in patients with LV systolic dysfunction (10, 11, 22, 23 ) . Furthermore, MPO concentration was not significantly correlated with findings of structural heart disease, systolic dysfunction, or diastolic dysfunction.
Other investigators have shown markers of inflammation and oxidative stress to be increased acutely in patients with ADHF (12, 13, 22, 23 ) . MPO is an inflammatory marker of particular interest, given its availability for clinical use and the accumulating data supporting a prognostic role for MPO in patients with cardiovascular disease. The present findings, however, suggest that previous observations by Ng et al. demonstrating a diagnostic utility for inflammatory markers, including C-reactive protein and MPO, are potentially limited to the identification of nonacute patients with undiagnosed LV dysfunction (24 ) . Asthma, chronic obstructive pulmonary disease, smoking, bronchitis, and pneumonia have all been associated with increased MPO concentrations (25) (26) (27) .
Inflammation has been linked to myocyte dysfunction, adverse LV remodeling, and poor outcomes in heart failure (28, 29 ) . Studies of mouse models of infarction and ischemia/reperfusion have shown that LV dilation and dysfunction are limited in MPO-null mice, implying that MPO plays a mechanistic role in remodeling (30, 31 ) . In fact, Tang and colleagues have shown that patients with stable chronic heart failure have higher concentrations of MPO than healthy controls (10 ) . In patients with advanced cardiomyopathy, higher MPO concentrations were associated with a higher prevalence of the combined endpoint of death or heart transplantation (11 ); however, the MPO values that were obtained (median, 303 pmol/L; IQR, 256 -530 pmol/L) were lower than the concentrations we observed (median, 566 pmol/L; IQR, 414 -827 pmol/ L). Although MPO seems to have a viable role for prognosis in stable patients with an established diagnosis of heart failure with severe systolic dysfunction, MPO concentration appears to be increased erratically in patients with acute dyspnea.
When applied to a population with dyspnea as a primary presentation, MPO did not predict 1-year survival. Even when we limited the analysis to patients with diagnosed heart failure, MPO was still not associated with mortality. Conversely, the established natriuretic peptide markers BNP and NT-proBNP and the soluble ST2 receptor are known to be significant predictors of death at 1 year in dyspnea populations (22, (32) (33) (34) . One explanation is that although inflammation may play a prominent role in late-stage heart failure and advanced states of ventricular remodeling, its prognostic potential is limited in a general dyspnea population, in which more benign, reversible etiologies may also play a role in increasing the MPO concentration (35 ) . Prior studies support the prognostic role of inflammatory markers, such as C-reactive protein or growth differentiation factor 15, in chronic heart failure (36, 37 ) .
Our study had several limitations. Echocardiography evaluations were not performed for all of the participants, although we believe the 82% completion rate compares favorably with other dyspnea studies (16, 38 ) . Although the 1-year follow-up data for the study population were complete for 97% of the patients, we did not report cause of death. Although unlikely, a longer follow-up might have unmasked a longer-term prognostic value for this marker. The strengths of the present study are its large, ethnically diverse co- hort of patients for which the diagnosis and prognosis of ADHF were validated with strong correlation to established biomarkers, structural cardiac abnormalities, and an adjudicated diagnosis of heart failure.
In conclusion, the circulating MPO concentrations, unlike natriuretic peptides, did not appear useful for establishing the etiology of dyspnea in patients presenting to an ED setting. In addition, MPO concentration was not correlated with LVEF or other cardiac structural abnormalities. Lastly, MPO concentrations did not provide significant prognostic information in dyspnea patients presenting to the ED, whereas natriuretic peptides, biomarkers that in part reflect cardiacfilling pressure, were significantly associated with heart failure diagnosis and 1-year mortality.
